IQVIA Response to FDA Statement
May. 16, 2018
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 16, 2018--IQVIA ™ (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. We also provide a select set of services to the FDA and other government agencies. Recently, we made a correction to a kilogram conversion measurement in the United States IQVIA National Sales Perspective (NSP) market research service affecting reported measurements for transdermal patches in the opioid market. This kilogram measurement is reported in the NSP market research service. This measurement conversion issue does not impact our widely used US and global dollar and unit information in NSP or information in any other IQVIA market research services, methodologies or offerings.
IQVIA’s internal processes had already identified the measurement conversion issue prior to the FDA’s notification. We notified our clients about this measurement conversion issue in April of this year. Ongoing steps have been undertaken to correct this measurement conversion issue in this offering.
We stand behind our data methodologies. We value our long-standing relationship with the FDA. We take the FDA’s concerns seriously and will continue working with the FDA to resolve these concerns to its satisfaction.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516006324/en/
CONTACT: IQVIA Media Relations
Tor Constantino, +1-484-567-6732
IQVIA Investor Relations
Andrew Markwick, +1-973-257-7144
KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT NORTH CAROLINA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY RESEARCH FDA SCIENCE
Copyright Business Wire 2018.
PUB: 05/16/2018 02:57 PM/DISC: 05/16/2018 02:57 PM